Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.

导出原文传递

翻译打印收藏纠错

作者： Shota,Omori ^[1] ; Hirotsugu,Kenmotsu ^[1] ; Masato,Abe ^[2] ; Reiko,Watanabe ^[3] ; Takashi,Sugino ^[2] ; Haruki,Kobayashi ^[1] ; Kazuhisa,Nakashima ^[1] ; Kazushige,Wakuda ^[1] ; Akira,Ono ^[1] ; Tetsuhiko,Taira ^[1] ; Tateaki,Naito ^[1] ; Haruyasu,Murakami ^[1] ; Yasuhisa,Ohde ^[4] ; Masahiro,Endo ^[5] ; Yasuto,Akiyama ^[6] ; Takashi,Nakajima ^[2] ; Toshiaki,Takahashi ^[7]

作者单位： Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, Shizuoka, 411-8777, Japan. ^[1] Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan. ^[2] Division of Pathology, National Cancer Center, Tokyo, Japan. ^[3] Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan. ^[4] Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan. ^[5] Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan. ^[6] Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Suntou-gun, Shizuoka, Shizuoka, 411-8777, Japan. t.takahashi@scchr.jp. ^[7]

关键词 Changes in PD-L1 expression EGFR tyrosine-kinase inhibitor (EGFR-TKI)Epidermal growth factor receptor (EGFR)Non-small cell lung cancer (NSCLC)Programmed death ligand 1 (PD-L1)